Subcutaneous rotenone exposure causes highly selective dopaminergic degeneration and α-synuclein aggregation

Experimental Neurology

Volumn 179, Issue 1, 2003, Pages 9-16

  Sherer, Todd B ^a   Kim, Jin Ho ^a,b   Betarbet, Ranjita ^a   Greenamyre, J Timothy ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Chosun University   (South Korea)

Author keywords

Complex I; Mitochondria; Oxidative stress; Parkinson's disease; Pesticides

Indexed keywords

ALPHA SYNUCLEIN; PESTICIDE; PHOSPHOPROTEIN DARPP 32; ROTENONE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANNULATION; CELL INCLUSION; CELL STRUCTURE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; GLOBUS PALLIDUS; JUGULAR VEIN; MALE; NERVE CELL; NERVE DEGENERATION; NONHUMAN; OSMOTIC PUMP; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; STRIATE CORTEX; STRIATONIGRAL DEGENERATION; SUBTHALAMIC NUCLEUS;

EID: 0037229425     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2002.8072     Document Type: Article

References (64)

1. Alam, M., and W. J. Schmidt. 2002. Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats. Behav. Brain Res. 136: 317-324.
2. Alam, Z. I., S. E. Daniel, A. J. Lees, D. C. Marsden, P. Jenner, and B. Halliwell. 1997. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69: 1326-1329.
3. Alexi, T., P. E. Hughes, B. Knusel, and A. J. Tobin. 1998. Metabolic compromise with systemic 3-nitropropionic acid produces striatal apoptosis in Sprague-Dawley rats but not in BALB/c ByJ mice. Exp. Neurol. 153: 74-93.
4. Barrientos, A., and C. T. Moraes. 1999. Titrating the effects of mitochondrial complex I impairment in the cell physiology. J. Biol. Chem. 274: 16188-16197.
5. Beal, M. F., E. Brouillet, B. G. Jenkins, R. J. Ferrante, N. W. Kowall, J. M. Miller, E. Storey, R. Srivastava, B. R. Rosen, and B. T. Hyman. 1993. Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci. 13: 4181-4192.
6. Betarbet, R., T. B. Sherer, G. Mackenzie, M. Garcia-Osuna, A. V. Panov, and J. T. Greenamyre. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3: 1301-1306.
7. Blum, D., D. Gall, L. Cuvelier, and S. N. Schiffmann. 2001. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. NeuroReport 12: 1769-1772.
8. Cardellach, F., M. J. Marti, J. Fernandez-Sola, C. Marin, J. B. Hoek, E. Tolosa, and A. Urbano-Marquez. 1993. Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease. Neurology 43: 2258-2262.
9. Conway, K. A., J. C. Rochet, R. M. Bieganski, and P. T. J. Lansbury. 2001. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294: 1257-1258.
10. Degli Esposti, M. 1998. Inhibitors of NADH-ubiquinone reductase: An overview. Biochim. Biophys. Acta 1364: 222-235.
11. Dexter, D. T., C. J. Carter, F. R. Wells, F. Javoy-Agid, Y. Agid, A. Lees, P. Jenner, and C. D. Marsden. 1989. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52: 381-389.
12. Ding, Q., and J. N. Keller. 2001. Proteasome inhibition in oxidative stress neurotoxicity: Implications for heat shock proteins. J. Neurochem. 77: 1010-1017.
13. Fahn, S., and G. Cohen. 1992. The oxidant stress hypothesis in Parkinson's disease: Evidence supporting it. Ann. Neurol. 32: 804-812.
14. Ferrante, R. J., J. B. Schulz, N. W. Kowall, and M. F. Beal. 1997. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not in the substantia nigra. Brain Res. 753: 157-162.
15. Floor, E., and M. G. Wetzel. 1998. Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J. Neurochem. 70: 268-275.
16. Giasson, B. I., J. E. Duda, I. V. Murray, Q. Chen, J. M., Souza, H. I. Hurtig, H. Ischiropoulos, J. Q. Trojanowski, and V. M. Lee. 2000. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290: 985-989.
17. Gorell, J. M., C. C. Johnson, B. A. Rybicki, E. L. Peterson, and R. J. Richardson. 1998. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 50: 1346-1350.
18. Haas, R. H., F. Nasirian, K. Nakano, D. Ward, M. Pay, R. Hill, and C. W. Shults. 1995. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Ann. Neurol. 37: 714-722.
19. Hastings, T. G. 1995. Enzymatic oxidation of dopamine: The role of prostaglandin H synthase. J. Neurochem. 64: 919-924.
20. Hensley, K., Q. N. Pye, M. L. Maidt, C. A. Stewart, K. A. Robinson, F. Jaffrey, and R. A. Floyd. 1998. Interaction of alpha-phenyl-N-tert-butyl nitrone and alternative electron acceptors with complex I indicates a substrate reduction site upstream from the rotenone binding site. J. Neurochem. 71: 2549-2557.
21. Hsu, L. J., Y. Sagara, A. Arroyo, E. Rockenstein, A. Sisk, M. Mallory, J. Wong, T. Takenouchi, M. Hashimoto, and E. Masliah. 2000. Alpha-synuclein promotes mitochondrial deficit and oxidative stress. Am. J. Pathol. 157: 401-410.
22. Iwatsubo, T., H. Yamaguchi, M. Fujimuro, H. Yokosawa, Y. Ihara, J. Q. Trojanowski, and V. M. Lee. 1996. Purification and characterization of Lewy bodies from the brains of patients with diffuse Lewy body disease. Am. J. Pathol. 148: 1517-1529.
23. + by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur. J. Pharmacol. 106: 455-456.
24. Jenner, P. 1998. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov. Disord. 13: 24-34.
25. Kanda, S., J. F. Bishop, M. A. Eglitis, Y. Yang, and M. M. Mouradian. 2000. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 97: 279-284.
26. Kitada, T., S. Asakawa, N. Hattori, H. Matsumine, Y. Yamamura, S. Minoshima, M. Yokochi, Y. Mizuno, and N. Shimizu. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392: 605-608.
27. Ko, L., N. D. Mehta, M. Farrer, C. Easson, J. Hussey, S. Yen, J. Hardy, and S. H. Yen. 2000. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. J. Neurochem. 75: 2546-2554.
28. Kowall, N. W., P. Hantraye, E. Brouillet, M. F. Beal, A. C. Mckee, and R. J. Ferrante. 2000. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. NeuroReport 11: 211-213.
29. Langston, J. W., P. Ballard, J. W. Tetrud, and I. Irwin. 1983. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979-980.
30. Lee, H. J., C. Choi, and S. J. Lee. 2002. Membrane-bound alpha-synuclein has a high aggregation propensity and the ability to seed the aggregation of the cytosolic form. J. Biol. Chem. 277: 671-678.
31. Lee, H. J., S. Y. Shin, C. Choi, Y. H. Lee, and S. J. Lee. 2001. Formation and removal of alpha-synuclein aggregates in cells exposed to mitochondrial inhibitors. J. Biol. Chem. 27: 27.
32. Leroy, E., R. Boyer, G. Auburger, B. Leube, G. Ulm, E. Mezey, G. Harta, M. J. Brownstein, S. Jonnalagada, T. Chernova, A. Dehejia, C. Lavedan, T. Gasser, P. J. Steinbach, K. D. Wilkinson, and M. H. Polymeropoulos. 1998. The ubiquitin pathway in Parkinson's disease. Nature 395: 451-452.
33. Lotharius, J., and K. L. O'Malley. 2000. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation: A novel mechanism of toxicity. J. Biol. Chem. 275: 38581-38588.
34. Mann, V. M., J. M. Cooper, D. Krige, S. E. Daniel, A. H. Schapira, and C. D. Marsden. 1992. Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease. Brain 115(Pt 2): 333-342.
35. Manning-Bog, A. B., A. L. Mccormack, J. Li, V. N. Uversky, A. L. Fink, and D. A. Di Monte. 2002. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice. J. Biol. Chem. 277: 1641-1644.
36. Matthews, R. T., P. Klivenyi, G. Mueller, L. Yang, M. Wermer, C. E. Thomas, and M. F. Beal. 1999. Novel free radical spin traps protect against malonate and MPTP neurotoxicity. Exp. Neurol. 157: 120-126.
37. McNaught, K. S., C. W. Olanow, B. Halliwell, O. Isacson, and P. Jennen. 2001. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat. Rev. Neurosci. 2: 589-594.
38. Menegon, A., P. G. Board, A. C. Blackburn, G. D. Mellick, and D. G. Le Couteur. 1998. Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet 352: 1344-1346.
39. Mizuno, Y., S. Ohta, M. Tanaka, S. Takamiya, K. Suzuki, T. Sato, H. Oya, T. Ozawa, and Y. Kagawa. 1989. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochem. Biophys. Res. Commun. 163: 1450-1455.
40. Neystat, M., T. Lynch, S. Przedborski, N. Kholodilov, M. Rzhetskaya, and R. E. Burke. 1999. Alpha-synuclein expression in substantia nigra and cortex in Parkinson's disease. Mov. Disord. 14: 417-422.
41. Nicklas, W. J., I. Vyas, and R. E. Heikkila. 1985. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin. 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36: 2503-2508.
42. Ouary, S., N. Bizat, S. Altairac, H. Menetrat, V. Mittoux, F. Conde, P. Hantraye, and E. Brouillet. 2000. Major strain differences in response to chronic systemic administration of the mitochondrial toxin 3-nitropropionic acid in rats: Implications for neuroprotection studies. Neuroscience 97: 521-530.
43. Parker, W. D., Jr., S. J. Boyson, and J. K. Parks. 1989. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann. Neurol. 26: 719-723.
44. Paxinou, E., Q. Chen, M. Weisse, B. I. Giasson, E. H. Norris, S. M. Rueter, J. Q. Trojanowski, V. M. Lee, and H. Ischiropoulos. 2001. Induction of alpha-synuclein aggregation by intracellular nitrative insult. J. Neurosci. 21: 8053-8061.
45. Pettus, E. H., R. Betarbet, B. Cottrell, D. C. Wallace, V. Madyastha, and J. T. Greenamyre. 2000. Immunocytochemical characterization of the mitochondrially encoded ND1 subunit of complex I (NADH:ubiquinone oxidoreductase) in rat brain. J. Neurochem. 75: 383-392.
46. Polymeropoulos, M. H., C. Lavedan, E. Leroy, S. E. Ide, A. Dehejia, A. Dutra, B. Pike, H. Root, J. Rubenstein, R. Boyer, E. S. Stenroos, S. Chandrasekharappa, A. Athanassiadou, T. Papapetropoulos, W. G. Johnson, A. M. Lazzarini, R. C. Duvoisin, G. Di Iorio, L. I. Golbe, and R. L. Nussbaum. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
47. Rideout, H. J., K. E. Larsen, D. Sulzer, and L. Stefanis. 2001. Proteasomal inhibition leads to formation of ubiquitin/alpha-synuclein-immunoreactive inclusions in PC12 cells. J. Neurochem. 78: 899-908.
48. Schapira, A. H., J. M. Cooper, D. Dexter, P. Jenner, J. B. Clark, and C. D. Marsden. 1989. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1: 1269.
49. Schulz, J. B., D. R. Henshaw, R. T. Matthews, and M. F. Beal. 1995. Coenzyme Q10 and nicotinamide and a free radical spin trap protect against MPTP neurotoxicity. Exp. Neurol. 132: 279-283.
50. Seaton, T. A., J. M. Cooper, and A. H. Schapira. 1997. Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Res. 777: 110-118.
51. Sherer, T. B., R. Betarbet, and J. T. Greenamyre. 2002. The rotenone model of Parkinson's disease in vivo: Selective striatal oxidative damage and caspase-3 activation in nigrostriatal neurons. Soc. Neurosci. Abstr. 653.2.
52. Sherer, T. B., R. Betarbet, A. K. Stout, S. Lund, M. Baptista, A. V. Panov, M. R. Cookson, and J. T. Greenamyre. 2002. An in vitro model of Parkinson's disease: Linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. J. Neurosci. 22: 7016-7026.
53. Sherer, T. B., P. A. Trimmer, K. Borland, J. K. Parks, J. P. Bennett, Jr., and J. B. Tuttle. 2001. Chronic reduction in complex I function alters calcium signaling in SH-SY5Y neuroblastoma cells. Brain Res. 891: 94-105.
54. Souza, J. M., B. I. Giasson, Q. Chen, V. M. Lee, and H. Ischiropoulos. 2000. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers: Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275: 18344-18349.
55. Spillantini, M. G., M. L. Schmidt, V. M. Lee, J. Q. Trojanowski, R. Jakes, and M. Goedert. 1997. Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
56. Sun, Z., J. Xie, and A. Reiner. 2002. The differential vulnerability of striatal projection neurons in 3-nitropropionic acid-treated rats does not match that typical of adult-onset Huntington's disease. Exp. Neurol. 176: 55-65.
57. 3H]di-hydrorotenone. J. Neurochem. 75: 2611-2621.
58. Thiffault, C., J. W. Langston, and D. A. Di Monte. 2000. Increased striatal dopamine turnover following acute administration of rotenone to mice. Brain Res. 885: 283-288.
59. Tofaris, G. K., R. Layfield, and M. G. Spillantini, 2001. Alpha-synuclein metabolism and aggregation is linked to ubiquitin-independent degradation by the proteasome. FEBS Lett. 509: 22-26.
60. Turrens, J. F., and A. Boveris, 1980. Generation of superoxide anion by the NADH dehydrogenase of bovine heart mitochondria. Biochem. J. 191: 421-427.
61. Uversky, V. N., J., Li, and A. L., Fink, 2001. Pesticides directly accelerate the rate of alpha-synuclein fibril formation: A possible factor in Parkinson's disease. FEBS Lett. 500: 105-108.
62. Vila, M., S., Vukosavic, V., Jackson-Lewis, M., Neystat, M., Jakowec, and S. Przedborski, 2000. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 74: 721-729.
63. Votyakova, T. V., and I. J., Reynolds, 2001. Δψm-Dependent and -independent production of reactive oxygen species by rat brain mitochondria. J. Neurochem. 79: 266-277.
64. Wooten, G. F. 1997. Neurochemistry and neuropharmacology of Parkinson's disease. In Movement Disorders: Neurologic Principles and Practice (R. L. Watts and Koller, Eds.), pp. 153-160. McGraw-Hill, New York.